Conditions: Prostate Cancer
Keywords: Prostate Cancer Bone Loss with Prostate Cancer Treatment of bone loss in patients undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer (PC).
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1468
Healthy volunteers: no

Brief summary:
This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: AMG 162 intervention 2: Placebo
Intervention descriptions: intervention 1: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30 intervention 2: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30

Protocol document: